methyl 2-(3,3-diethylthioureido)benzoate | 1086685-17-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(3,3-diethylthioureido)benzoate
• 英文别名: methyl 2-(3,3-diethyl-thioureido)benzoate；methyl 2-(diethylcarbamothioylamino)benzoate
• CAS: 1086685-17-7
• 化学式: C₁₃H₁₈N₂O₂S
• 分子量: 266.364
• InChiKey: ZWSGCDBJMCWODL-UHFFFAOYSA-N

物化性质

• 沸点：
  360.9±44.0 °C(Predicted)
• 密度：
  1.183±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  73.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 2-(3,3-diethylthioureido)benzoate 在 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以78%的产率得到2-(3,3-diethylthioureido)benzoic acid
  参考文献：
  名称：

  Aromatic 2-(Thio)ureidocarboxylic Acids As a New Family of Modulators of Multidrug Resistance-Associated Protein 1: Synthesis, Biological Evaluation, and Structure−Activity Relationships

  摘要：

  Four series of aromatic carboxylic acids were prepared with a urea or thiourea moiety at the neighboring position to the carboxyl group and benzene or thiophene as aromatic scaffold. Using a calcein AM assay, these compounds were evaluated as inhibitors of multidrug resistance-associated protein I (MRP1) and selected compounds were examined toward P-glycoprotein (P-gp) as well as breast cancer resistance protein (BCRP) to assess selectivity for MRP1. Two 2-thioureidobenzo[b]-thiophene-3-carboxylic acids (48, 49) were identified as particularly potent inhibitors of MRP1, with IC50 values of around 1 mu M. The structural features of this new family or nontoxic MRP1 inhibitors include a (thio)urea disubstituted with preferentially two alkyl groups at the terminal nitrogen and an additional fused aromatic ring.

  DOI：

  10.1021/jm900688v
• 作为产物：
  描述：

  2-异硫氰基苯甲酸甲酯 、 二乙胺 以 二氯甲烷 为溶剂， 反应 3.0h， 以71%的产率得到methyl 2-(3,3-diethylthioureido)benzoate
  参考文献：
  名称：

  2-Amino- and 2-Alkylthio-4H-3,1-benzothiazin-4-ones: Synthesis, Interconversion and Enzyme Inhibitory Activities

  摘要：

  2-sec-氨基金刚烷-4H-3,1-苯并噻嗪-4-酮的合成途径已被探索。化合物2可通过不同条件下，从甲基2-硫脲苄酯1、2-硫脲苯甲酸3和新型的2-硫脲苯甲酰胺6中得到。2-烷硫基-4H-3,1-苯并噻嗪-4-酮5则通过两步路线从邻氨基苯甲酸制备得到。苯并噻嗪酮2和5均在环裂解反应中分别生成硫脲1和6。对十二种苯并噻嗪酮进行了作为八种蛋白酶和酯酶抑制剂的评估，以识别出一种对人类组织蛋白酶L具有选择性抑制作用的2b和一种对人类白细胞弹性蛋白酶具有选择性抑制作用的5i。

  DOI：

  10.3390/molecules14010378

文献信息

• Potassium Channel Modulators
  申请人：Perez-Medrano Arturo

  公开号：US20120122890A1

  公开（公告）日：2012-05-17

  Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein G 1 , R 2 , R 1a , R 1b , X, X 1 , X 2 , X 3 , R x , J, k, n, q, and t are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

  本文披露了式（I）的KCNQ钾通道调节剂，其中G 1 ，R 2 ，R 1a ，R 1b ，X，X 1 ，X 2 ，X 3 ，R x ，J，k，n，q和t如规范中所定义。还描述了包含这些化合物的组合物；以及使用这些化合物和组合物治疗疾病和疾病的方法。
• 2, 3-diamino-quinazolinone derivatives and their medical use
  申请人：Neurosearch A/S

  公开号：US08178544B2

  公开（公告）日：2012-05-15

  This invention provides 2,3-diamino-quinazolinone compounds of Formula (I) stereoisomers thereof, pharmaceutically-acceptable addition salts thereof, and N-oxides thereof, wherein the variables are as defined in the specification. The 2,3-diamino-quinazolinone compounds have medical utility. The 2,3-diamino-quinazolinone compounds can be used for the manufacture of medicaments, including pharmaceutical compositions. This invention also provides methods of treating disorders, diseases, or conditions which are responsive to activation of Kv7 channels.

  这项发明提供了2,3-二氨基喹唑啉酮化合物的公式(I)及其立体异构体、药学上可接受的加合物盐以及N-氧化物，其中变量如规范中所定义。2,3-二氨基喹唑啉酮化合物具有医疗用途。2,3-二氨基喹唑啉酮化合物可用于制造药物，包括制药组合物。此发明还提供了治疗对Kv7通道激活有反应的疾病、疾病或状况的方法。
• NOVEL 2, 3-DIAMINO-QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE
  申请人：Jessen Carsten

  公开号：US20100160315A1

  公开（公告）日：2010-06-24

  This invention relates to novel 2,3-diamino-quinazolinone derivatives having medical utility, to use of the 2,3-diamino-quinazolinone derivatives of the invention for the manufacture of a medicament, to pharmaceutical compositions comprising the 2,3-diamino-quinazolinone derivatives of the invention, and to methods of treating a disorder, disease or a condition of a subject, which disorder, disease or condition is responsive to activation of K v 7 channels.

  本发明涉及具有医疗用途的新型2,3-二氨基喹唑啉酮衍生物，涉及使用本发明的2,3-二氨基喹唑啉酮衍生物制造药物，涉及包含本发明的2,3-二氨基喹唑啉酮衍生物的制药组合物，以及涉及治疗与Kv7通道激活有关的主体的紊乱、疾病或状况的方法。
• Potassium channel modulators
  申请人：Perez-Medrano Arturo

  公开号：US08609674B2

  公开（公告）日：2013-12-17

  Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein G1, R2, R1a, R1b, X, X1, X2, X3, Rx, J, k, n, q, and t are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

  本文披露了公式（I）的KCNQ钾通道调节剂，其中G1，R2，R1a，R1b，X，X1，X2，X3，Rx，J，k，n，q和t的定义如规范中所定义。还描述了包含这些化合物的组合物；以及使用这些化合物和组合物治疗疾病和病症的方法。
• Novel 2,3-diamino-quinazolinone derivatives and their medical use
  申请人：NeuroSearch A/S

  公开号：EP2465504A1

  公开（公告）日：2012-06-20

  This invention relates to novel 2,3-diamino-quinazolinone derivatives having medical utility, to use of the 2,3-diamino-quinazolinone derivatives of the invention for the manufacture of a medicament, to pharmaceutical compositions comprising the 2,3-diamino-quinazolinone derivatives of the invention, and to methods of treating a disorder, disease or a condition of a subject, which disorder, disease or condition is responsive to activation of Kv7 channels.

  本发明涉及具有医疗用途的新型 2,3-二氨基喹唑啉酮衍生物，涉及使用本发明的 2,3-二氨基喹唑啉酮衍生物制造药物，涉及包含本发明的 2,3-二氨基喹唑啉酮衍生物的药物组合物，还涉及治疗受试者的紊乱、疾病或病症的方法，该紊乱、疾病或病症对 Kv7 通道的激活有反应。